1. Correction to « Population Pharmacokinetic Analysis of Atomoxetine and its Metabolites in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder ». Clin Pharmacol…

1. Abanoz E, Ulger Ozbek D, Güven Say A, Uzun Cicek A. Dysregulation of the orexin-leptin-ghrelin axis and its associations…

1. ADHD drug treatment and risk of suicidal behaviours, substance misuse, accidental injuries, transport accidents, and criminality: emulation of target…

1. Drugs for ADHD. Med Lett Drugs Ther. 2025; 67(1736): 137-44. Lien vers le texte intégral (Open Access ou abonnement)…

1. Correction to « Impact of the polygenic risk scores for attention-deficit/hyperactivity disorder in Alzheimer’s disease ». Alzheimers Dement. 2025; 21(7): e70467.…

1. Correction: The effects of tryptophan loading on Attention Deficit Hyperactivity Disorder in adults: A remote double blind randomised controlled…

1. Replying to the comment on « The mediated model of PTSD between ADHD symptoms and alcohol abuse in a population…

1. Abadi A, Cetkovich-Bakmas M, Klijnjan H, Echavarria N, Lischinsky A, López P, Michanie C, Maresca T, Remedi C, Rovere…

1. FDA-Approved Drugs to Treat ADHD. J Psychosoc Nurs Ment Health Serv. 2025; 63(3): 5-6. Lien vers le texte intégral…